Rogue Funds, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned 8.59% net of fees in the quarter. This quarter, the Fund's volatility has increased significantly, and the firm anticipates that it will continue to do so. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.

In its fourth quarter 2024 investor letter, Rogue Funds emphasized stocks such as ASP Isotopes Inc. (NASDAQ:ASPI). ASP Isotopes Inc. (NASDAQ:ASPI) is a development stage advanced materials company specialized on the production, distribution, marketing, and sale of isotopes. The one-month return of ASP Isotopes Inc. (NASDAQ:ASPI) was -6.54%, and its shares gained 86.27% of their value over the last 52 weeks. On February 14, 2025, ASP Isotopes Inc. (NASDAQ:ASPI) stock closed at $5.29 per share with a market capitalization of $377.654 million.

Rogue Funds stated the following regarding ASP Isotopes Inc. (NASDAQ:ASPI) in its Q4 2024 investor letter:

"As you all know, I visited ASP Isotopes Inc. (NASDAQ:ASPI) a couple weeks ago and I was impressed with both who I met and the facilities that I saw. I think that the company is extremely close to reporting decent revenues that will change how the market views the company. Currently, it is trading as a pure nuclear entity, but the medical isotope side of the business is extremely underrated and could see huge TAM expansion. Their medical isotope business will maintain 80%+ margins, they will only have one or two competitors for each one, and in some cases, they will have zero competitors. Some of the isotopes needed aren’t even being produced but have extremely useful potential in fighting cancer which ASP Isotopes can address. The nuclear side of the business has accelerated since our last letter with deals with both TerraPower and NECSA becoming public. Production of Silicon-28 should begin shortly, and I expect academic institutions to begin producing public results utilizing the benefits of pure Silicon-28 so we can get a better idea of the TAM. With their current Silicon-28 facility they will be set to produce 10x as much Silicon as the next closest competitor and are the only ones who can produce it in a directly usable form. This is an incredible opportunity for the Fund, and it has already begun to pay off handsomely. Due to our large at-cost position, it will continue to have a strong impact on the Funds volatility. We feel extremely confident in this position going forward. It is our largest position and will continue to be so for the foreseeable future, and we have not sold any shares since the initial short report."

A chemist examining a beaker of colored liquid and advanced pharmaceuticals.

ASP Isotopes Inc. (NASDAQ:ASPI) is not on our list of 30 Most Popular Stocks Among Hedge Funds.  As per our database, 6 hedge fund portfolios held ASP Isotopes Inc. (NASDAQ:ASPI) at the end of the third quarter which was 3 in the previous quarter. While we acknowledge the potential of ASP Isotopes Inc. (NASDAQ:ASPI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article we discussed ASP Isotopes Inc. (NASDAQ:ASPI) and shared Rogue Funds' views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.